CYP19A1 and benign prostatic hyperplasia: Lots of the researchers revealed that several kinds of constituents including the fatty acids, polyphenols, flavonoids, phytosterols, alkanoids may be responsible for BPH inhibitory activities of phytotherapy and the suggested mechanisms includes 5α-reductase inhibitor, α1-adrenoceptor antagonist, aromatase inhibitor, anti-androgen, growth factor inhibitor, and so on [23–25].